Cyclacel Pharmaceuticals, Inc.
17 clinical trials · Sponsor
◉ Watch Cyclacel Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects (NCT05817890) | Cyclacel Pharmaceuticals, Inc. | 2023-03-03 |
| A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma (NCT05358379) | Cyclacel Pharmaceuticals, Inc. | 2022-04-14 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) (NCT05168904) | Cyclacel Pharmaceuticals, Inc. | 2021-10-22 |
| A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma (NCT04983810) | Cyclacel Pharmaceuticals, Inc. | 2021-07-12 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS (NCT04017546) | Cyclacel Pharmaceuticals, Inc. | 2019-08-02 |
| A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS (NCT03884829) | Cyclacel Pharmaceuticals, Inc. | 2019-03-25 |
| CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL (NCT03739554) | Cyclacel Pharmaceuticals, Inc. | 2019-01-25 |
Track Cyclacel Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.